Mar 08,2019

Powering AI To Create A Patient-Centric Ecosystem

Creating efficient workflows and disrupting workforces are two topics that spark decision makers to ask: “How does this affect my industry?” Healthcare providers are among those who are looking for ways to improve patients’ healthcare journey throughout medical systems using artificial intelligence. Intelligent dermatology software, such as DermEngine, uses these powerful AI algorithms to recognize the most subtle changes in skin spots and other lesions with the Visual Search feature.

PRODUCT

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 06,2019

New McGill University Study Shows that a Promising eHealth App called Belong Enhances the Patient Experience with Cancer

Belong.Life, the world's largest interactive social network for cancer patients, caregivers and healthcare professionals, announced today that according to a new Study from McGill University, its personalized eHealth application shows promise for timely patient support, engagement, and symptom management. According to preliminary findings presented by McGill University's graduate student Saima Ahmed at the 2018 Machine Learning for Healthcare Annual Research Meeting at Stanford University, patients rate Belong very high on quality metrics and reported the app gives them a sense of control, feeling less alone in their cancer journey.

CLINICAL STUDY

#mobile app

#ml

View Analyst & Ambassador Comments
Go to original news
Mar 25,2019

MetaOptima Team Awarded The ISIC 2018 Challenge Disease Classification Prize

The goal of ISIC 2018: Skin Lesion Analysis Towards Melanoma Detection is to help participants develop image analysis tools to enable the automated diagnosis of melanoma from dermoscopic images. The ISIC 2018 challenge consisted of three tasks, with the MetaOptima Team focusing on the third titled “Task 3: Disease Classification”. The objective was to design a method that can automatically diagnose an image of a skin lesion as one of the following seven skin diseases: melanoma, melanocytic nevus, basal cell carcinoma, actinic keratosis, benign keratosis, dermatofibroma, or a vascular lesion.

View Analyst & Ambassador Comments
Go to original news
Mar 13,2019

DermEngine’s compliance to the General Data Protection Regulation (GDPR)

Europe’s pass of the General Data Protection Regulation (GDPR) last May brought many changes to the way information privacy is to be handled, with a particular focus in the handling of healthcare data.1 This article will discuss how the features and tools available in the dermatology software DermEngine are compliant with GDPR for maximized security and privacy.

PRODUCT

#ai/software

#platform

View Analyst & Ambassador Comments
Go to original news
Mar 04,2019

A New Machine Learning Model can Classify Lung Cancer Slides at the Pathologist Level

Machine learning has improved dramatically in recent years and shown great promise in the field of medical image analysis. A team of research specialists at Dartmouth's Norris Cotton Cancer Center have utilized machine learning capabilities to assist with the challenging task of grading tumor patterns and subtypes of lung adenocarcinoma, the most common form of the leading cause of cancer-related deaths worldwide.

CLINICAL STUDY

#ai/software

#ml

View Analyst & Ambassador Comments
Go to original news
Mar 01,2019

Flatiron Health’s OncoEMR is Top-Rated for Overall Satisfaction by KLAS’ 2019 Medical Oncology Performance Report

Flatiron Health today announced its electronic health record (EHR) OncoEMR®, outperformed all other vendors in 11 out of 20 “key performance indicators” in KLAS’ 2019 Medical Oncology Performance Report, including “Overall Product Quality,” “Ease of Use” and “Overall Satisfaction.”

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Mar 20,2019

Voluntis announces end of Roche Pharma France collaboration for Zemy solution

Voluntis (Euronext Paris, Ticker: VTX – ISIN: FR0004183960), a company specializing in digital therapeutics, announces Roche Pharma France’s decision not to pursue ZEMY’s development in breast cancer. The collaboration between Roche Pharma France and Voluntis on this project will end at the conclusion of the feasibility clinical study currently being conducted by Roche Pharma France, end of April 2019. The contract between Roche Pharma France and Voluntis, signed in October 2015, aimed to develop and distribute the ZEMY solution in breast cancer, based on the Theraxium Oncology platform.

View Analyst & Ambassador Comments
Go to original news
Apr 02,2019

Dermoscopy: Not Just For Dermatologists Anymore

Dermoscopy is a powerful method for the early detection of skin cancer and other conditions, improving diagnostic accuracy by as much as 35%. In the past, the practice of dermoscopy was limited to the dermatologist- after all, it is the tool of their trade. The drawback of this framework means that dermatologists are stuck doing the heavy lifting (imaging, administrative work). How can other healthcare providers relieve this pressure? Mobile dermoscopes are designed to capture high quality images straight to your smartphone or a dermatology app.

#connected device

#mobile app

View Analyst & Ambassador Comments
Go to original news
Apr 11,2019

How Can AI Quicken Imaging Workflows?

Dermatologists are already stretched thin, with 623 specialists serving Canada’s population of over 37 million and many rural areas left without a professional at all. How can DermEngine’s artificial intelligence-based tools assist medical professionals quickly and effectively serve high-priority patients?

#ai/software

View Analyst & Ambassador Comments
Go to original news
Apr 01,2019

Foundation Medicine and Flatiron Health Publish Validation of Clinico-Genomic Database as a Platform to Advance Oncology Therapeutics Development and Personalized Cancer Care

Foundation Medicine and Flatiron Health today announced the publication of study results in the Journal of the American Medical Association validating that real-world clinico-genomic data obtained during the course of routine patient care can yield scientifically and clinically meaningful insights. These insights can serve as real-world evidence to advance research and discovery in oncology, and may also ultimately inform clinical guidelines.

CLINICAL STUDY

#platform

#rwe

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY